Brain Tumor Treatments: Less-Toxic
Sponsored By
Brain tumor book
Please Click On The Above Banner For More Details
Braintumor Website

Search Term: Less-Toxic
Please scroll down past the trials to see pages on this site about this topic!

<
  Treatment Location Last Updated
Details Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Philadelphia, PA USA 11/08/2008
Details Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Memphis, TN USA 11/08/2008
Details Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Durham, NC USA 11/08/2008
Details Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Seattle, WA USA 11/08/2008
Details Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Chicago, IL USA 11/08/2008
Details Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Pittsburgh, PA USA 11/08/2008
Details Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Boston, MA USA 11/08/2008
Details Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma San Francisco, CA USA 11/08/2008
Details Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Washington, DC USA 11/08/2008
Details Bevacizumab (Avastin) and Irinotecan (CPT-11) in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Bethesda, MD USA 11/08/2008
Details Effect of NovoTTF-100A in Recurrent GBM Pittsburgh, PA USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Chicago, IL USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Manhasset, NY USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM New York, NY USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Cleveland, OH USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Edison, NJ USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM NEW YORK CITY, NY USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Chicago, IL 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Evanston, IL USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Zürich , Switzerland 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Lausanne, Switzerland 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM New York, NY USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Milwaukee, WI USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Cleveland, OH USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Innsbruck, Austria 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Prague, Czech Republic 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Augsburg, Germany 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Bridgeport, CT USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Boston, MA USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Burlington, MA USA 11/05/2008
Details Effect of NovoTTF-100A in Recurrent GBM Charlottesville, VA USA 11/05/2008
Details A Phase II Trial of Thalidomide in combination with Temozolomide or CPT-11 in patients with recurrent anaplastic gliomas or glioblastoma multiforme Houston, TX USA 10/27/2008
Details BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma Charlottesville, VA USA 10/20/2008
Details CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan New York, NY USA 10/09/2008
Details CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan Houston, TX USA 10/09/2008
Details CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan Durham, NC USA 10/09/2008
Details CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan San Francisco, CA USA 10/09/2008
Details CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan Charlottesville, VA USA 10/09/2008
Details CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan Boston, MA USA 10/09/2008
Details Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Pittsburgh, PA USA 10/09/2008
Details Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma New York, NY USA 10/09/2008
Details Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Charlottesville, VA USA 10/09/2008
Details Phase I/II Study of Sorafenib and Temsirolimus (CCI-779) in Patients With Recurrent Glioblastoma Charlottesville, VA USA 10/09/2008
Details Phase I/II Study of Sorafenib and Temsirolimus (CCI-779) in Patients With Recurrent Glioblastoma Bismarck, ND USA 10/09/2008
Details Phase I/II Study of Sorafenib and Temsirolimus (CCI-779) in Patients With Recurrent Glioblastoma Rochester, MN USA 10/09/2008
Details Phase I/II Study of Sorafenib and Temsirolimus (CCI-779) in Patients With Recurrent Glioblastoma Jacksonville, FL USA 10/09/2008
Details Phase I/II Study of Sorafenib and Temsirolimus (CCI-779) in Patients With Recurrent Glioblastoma Scottsdale/Phoenix, AZ USA 10/09/2008
Details A Phase II Study of TLN-4601 in Patients With Glioblastoma Multiforme Toronto, Ontario, CANADA 09/28/2008
Details A Phase II Study of Bevacizumab (Avastin) Plus Temodar and Tarceva After Radiation Therapy and Temodar in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Who Are Stable Following Radiation San Francisco, CA USA 04/27/2008
Details Phase I/II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme Houston , TX 04/27/2008
Details Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Durham, NC USA 04/27/2008
Details Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme New York, NY USA 04/27/2008
Details Phase 2, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 Monotherapy and Combination Therapy With Irinotecan in Patients With Recurrent Glioblastoma Multiforme Boston, MA USA 04/27/2008
Details Phase I / II Adaptive Randomized Trial of Vorinostat, Isotretinoin and Carboplatin in Adults with Recurrent Glioblastoma Multiforme Houston, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Durham, NC USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Houston, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Los Angeles, CA USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma New York, NY USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma San Antonio, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Bethesda, MD USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Houston, TX USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Madison, WI USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Pittsburgh, PA USA 04/15/2008
Details Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Boston, MA USA 04/15/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Chicago, IL USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Phoenix, AZ USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Detroit, MI USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Boston, MA USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Winston-Salem, NC USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Columbus, OH USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Edison, NJ USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Orlando, FL USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Jacksonville, FL USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Memphis, TN USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Buffalo, NY USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 La Jolla, CA USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Columbus, OH USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Evanston, IL USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Sacramento, CA USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Palo Alto, CA USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Englewood, CO USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Aurora, CO USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Portland, OR USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Seattle, WA USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Madison, WI USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Edmonton, Alberta, CANADA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Winnipeg, Manitoba, CANADA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Moncton, New Brunswick, CANADA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Ottawa, Ontario, CANADA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Toronto, Ontario, CANADA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Nashville, TN USA 03/01/2008
Details NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 Kingston, Ontario, CANADA 03/01/2008
Details Gliogene: Brain Tumor Linkage Study Tampa, FL USA 01/17/2008
Details Gliogene: Brain Tumor Linkage Study Boston, MA USA 01/17/2008
Details Gliogene: Brain Tumor Linkage Study San Francisco, CA USA 01/17/2008
Details Gliogene: Brain Tumor Linkage Study New York, NY USA 01/17/2008
Details Gliogene: Brain Tumor Linkage Study Houston, Tx USA 01/17/2008
Details A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas New York, NY USA 08/26/2007
Details A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Cincinnati,, OH USA 08/26/2007
Details A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Columbus, OH USA 08/26/2007
Details A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas Toronto, Ontario, CANADA 08/26/2007
Details Determination of the In-Tumor-Concentration of Imatinib Mesylate (Gleevec) in Malignant Glioma After Oral Administration Baltimore, MD USA 08/20/2007
Details A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas Vista, CA USA 08/20/2007
Details Eligibility Screening Of Patients With Central Nervous System Tumors For The National Cancer Institute`s (NCI) Clinical Research Protocols Bethesda, MD USA 08/20/2007